Compare ResMed Inc. (RMD) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? ResMed Inc. trades at $225 (market cap $32.61B), while iShares 10 20 Year Treasury Bond ETF trades at $96.56. The key difference: ResMed Inc. pays a 1.17% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and ResMed Inc. is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| RMD | TLH | |
|---|---|---|
Market Cap | $32.61B | — |
Sector | Health | Fixed Income |
52-Week High | $293.73 | $105.36 |
52-Week Low | $182.82 | $96.39 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
TLH trades at $96.62 with minimal daily movement (+0.24%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $97 and support at $96. Recent dividend payments of $0.38, $0.36, and $0.41 in mid-2026 indicate ongoing shareholder returns despite the challenging technical backdrop.
The outlook remains cautious with bearish technical signals dominating. Key resistance at $97 must be breached for bullish momentum. Dividend consistency provides some stability, but the lack of fundamental data and weak technical structure suggests limited near-term upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
